Literature DB >> 19447144

Performance of IgG and IgG1 anti-HTLV-1 reactivity by an indirect immunofluorescence flow cytometric assay for the identification of persons infected with HTLV-1, asymptomatic carriers and patients with myelopathy.

Jordana Grazziela Alves Coelho-dos-Reis1, Olindo Assis Martins-Filho, Gustavo Eustáquio Alvim de Brito-Melo, Sandra Gallego, Anna Bárbara Carneiro-Proietti, Jaqueline Gontijo Souza, Edel Figueiredo Barbosa-Stancioli.   

Abstract

In this study, the performance of IgG and IgG1 anti-HTLV-1 reactivity obtained by a flow cytometric assay was evaluated to verify its applicability for the diagnosis of persons infected with HTLV-1, including asymptomatic carriers and patients with myelopathy. The ability to identify patients with myelopathy among persons infected with HTLV-1 was also examined. Western blot assays were performed to assess the reactivity profiles of sera from asymptomatic carriers and patients with myelopathy against viral proteins. The data showed that IgG1 detected by flow cytometric assay is effective for the diagnosis of persons infected with HTLV-1 with 97% sensitivity and 100% specificity. IgG and IgG1 exhibited high performance in distinguishing patients with myelopathy from asymptomatic carriers. Using serum dilutions and cut-off points established previously a second HTLV-1 carrier group was tested using flow cytometric assay to detect IgG and IgG1. The data demonstrated sensitivity of 93% and 98%, respectively, confirming the high reactivity of persons infected with HTLV-1 detected by this method. Western blot assays confirmed the high specificity of MT-2 cells as a reliable source of viral antigen since only sera from persons infected with HTLV-1 recognised MT-2 proteins. Furthermore, a high reactivity to Gag and Env proteins was observed, especially among patients with myelopathy. These data suggest that flow cytometric detection of IgG1 is a valuable, non-conventional serological method to diagnose HTLV-1 infection and for research purposes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19447144     DOI: 10.1016/j.jviromet.2009.05.007

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  4 in total

1.  Quantitative differences in HTLV-I antibody responses: classification and relative risk assessment for asymptomatic carriers and ATL and HAM/TSP patients from Jamaica.

Authors:  Yoshimi Enose-Akahata; Anna Abrams; Kory R Johnson; Elizabeth M Maloney; Steven Jacobson
Journal:  Blood       Date:  2012-02-07       Impact factor: 22.113

2.  A reduction of viral mRNA, proteins and induction of altered morphogenesis reveals the anti-HTLV-1 activity of the labdane-diterpene myriadenolide in vitro.

Authors:  Camila Pacheco Silveira Martins; Orlando Abreu Gomes; Marina Lobato Martins; Luciana Debortoli de Carvalho; Jaqueline Gontijo de Souza; Flavio Guimaraes Da Fonseca; Rodrigo Gonçalves Silva dos Santos; Margareth Spangler Andrade; Carlos Leomar Zani; Elaine Maria de Souza-Fagundes; Edel Figueiredo Barbosa-Stancioli
Journal:  BMC Microbiol       Date:  2014-12-24       Impact factor: 3.605

3.  A New Flow Cytometry-Based Single Platform for Universal and Differential Serodiagnosis of HTLV-1/2 Infection.

Authors:  Luciene Pimenta de Paiva; Jordana Grazziela Alves Coelho-Dos-Reis; Bruno Caetano Trindade; Vanessa Peruhype-Magalhães; Márcio Sobreira Silva Araújo; Juan Jonathan Gonçalves; Ana Caroline Nogueira; Júlia Pereira Martins; Ágata Lopes Ribeiro; Ana Lucia Starling; Luiz Carlos Júnior Alcântara; Maísa Aparecida Ribeiro; Anna Bárbara de Freitas Carneiro-Proietti; Ester Cerdeira Sabino; Kelly Alves Bicalho; Andréa Teixeira-Carvalho; Olindo Assis Martins-Filho
Journal:  Front Immunol       Date:  2022-04-14       Impact factor: 8.786

4.  A flow cytometry-based workflow for detection and quantification of anti-plasmodial antibodies in vaccinated and naturally exposed individuals.

Authors:  Anthony Ajua; Thomas Engleitner; Meral Esen; Michael Theisen; Saadou Issifou; Benjamin Mordmüller
Journal:  Malar J       Date:  2012-11-06       Impact factor: 2.979

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.